Boukhvalova, Marina S <br/><br/>
The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.  [electronic resource] 

 -  Vaccine  Jun 2006 
 - 5027-35 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>0264-410X 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2006.03.064  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--pharmacology<br/>Animals<br/>Cytokines--antagonists & inhibitors<br/>Gene Expression Regulation<br/>Lipid A--analogs & derivatives<br/>Lung--metabolism<br/>Respiratory Syncytial Virus Vaccines--adverse effects<br/>Respiratory Syncytial Viruses--immunology<br/>Sigmodontinae--immunology<br/>Toll-Like Receptor 4--agonists